Safety and efficacy of interleukin-6-receptor inhibitors in the treatment of neuromyelitis optica spectrum disorders: a meta-analysis

Overview of attention for article published in BMC Neurology, November 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)
Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

policy: 1 policy source

twitter: 6 X users

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 14 Mendeley

Summary Policy documents X Dimensions citations

So far, Altmetric has seen 7 X posts from 6 X users, with an upper bound of 1,748 followers.

11-16-2021: Actemra (tocilizumab) performed extremely well for treating neuromyelitis optica spectrum disorders https://t.co/9cYz565kTb https://t.co/03bw6OPdp4 https://t.co/GimLkHnr9a https://t.co/cUbUkiF07Y https://t.co/cQhmoXnrpQ https://t.co/8QBx7jhZRE

15 Aug 2022

Reply Repost Favourite

New NNT→Safety and efficacy of interleukin-6-receptor inhibitors in the treatment of neuromyelitis optica spectrum disorders: a meta-analysis https://t.co/Ti8i36VZo1

30 Nov 2021

Reply Repost Favourite

RT @kharel560182: We are pleased to share our article "Safety and efficacy of interleukin-6-receptor inhibitors in treatment of neuromyelit…

25 Nov 2021

Reply Repost Favourite

Safety and efficacy of interleukin-6-receptor inhibitors in the treatment of neuromyelitis optica spectrum disorders: a meta-analysis https://t.co/GGKXwLf9hf

24 Nov 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 3 additional X posts.